Agreement Between Guideline Thresholds Using an "All-in-One" Device to Measure Office, Home, and Ambulatory Blood Pressures.

"data s1 tables s1-s5 figures s1-s4 click here for additional data file."

"Disclosures Dr Kario has received research grants from Omron Healthcare Co, Ltd, A&D Co, Ltd, and Fukuda Denshi Co, Ltd; and Dr Nishizawa has received honoraria for lectures from Daiichi‐Sankyo Co, Ltd, and Novartis Pharma K.K. The remaining authors have no disclosures to report."

"Sources of Funding This study was supported in part by funds from A&D Co, Ltd, and Otsuka Medical Devices Co, Ltd, and by a grant from the Foundation for the Development of the Community (Tochigi, Japan)."

"The HI‐JAMP study (University Hospital Medical Information Network trials registration: UMIN000029151) is a Japanese, nationwide, multicenter, general practitioner–based, prospective trial that has 2 key aims. The first is to investigate the ability of different BP parameters (office BP, home BP, and ambulatory BP) obtained by a single all‐in‐one BP monitoring device (TM‐2441; A&D Co, Tokyo, Japan) to predict cardiovascular events, and the second is to investigate relationships between BP parameters and individual environmental (temperature and atmospheric pressure) and lifestyle (physical activity) factors for which data are obtained by sensors incorporated into the BP monitoring device. After approval of the study protocol by the Jichi Medical University Bioethics Committee for Medical Research (Tochigi, Japan), the study was started in 2017. Recruitment was completed in 2020, and annual follow‐up will continue until March 31, 2026., All participants provided written informed consent."